Catalent invests over $27 million to commercialize Zydis Ultra7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.
Catalent Pharma Solution is to invest more than $27 million to commercialize its next-generation oral disintegrating tablet (ODT) technology, Zydis Ultra. The technology allows an increased drug load and taste masking to be incorporated into the company’s Zydis ODT dosage form, which is a unique freeze-dried tablet that disperses almost instantly in the mouth without water.
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT, while maintaining its speed of dispersion and superior mouth feel. To date, more than 36 products have been launched using Zydis technology in more than 60 countries. The novel coating technology significantly expands the range of drug candidates that can be formulated using the Zydis ODT platform, including analgesics, anti-allergy treatments and anti-infectives.
Zydis is recognized as one of the world’s best performing ODTs, and has well-established advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience, particularly within certain patient populations such as geriatrics, pediatrics and patients suffering from disorders of the central nervous system.
“Our team of scientists has been working on the next generation of ODT formulations for several years, to leverage the advantages that the dose form brings to patients in terms of convenience and increased drug compliance,” said Jonathan Arnold, President, Oral Drug Delivery at Catalent. “We have been collaborating with several partners on specific products utilizing the Zydis Ultra technology, and this investment coincides with these development programs reaching proof of concept and full development stages.”
Catalent’s 250,000 sq. ft. site in Swindon, UK houses the company’s Zydis fast dissolving tablet development and manufacturing operation, which produces over one billion ODTs annually and employs more than 600 people.
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation